Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Johnson and Johnson
McKinsey
Boehringer Ingelheim
Accenture
Julphar
McKesson
Queensland Health
Express Scripts
Teva

Generated: October 18, 2017

DrugPatentWatch Database Preview

Sugammadex sodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for sugammadex sodium and what is the scope of sugammadex sodium freedom to operate?

Sugammadex sodium
is the generic ingredient in one branded drug marketed by Organon Sub Merck and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sugammadex sodium has fifty-four patent family members in twenty-nine countries and eleven supplementary protection certificates in ten countries.

One supplier is listed for this compound.

Summary for Generic Name: sugammadex sodium

US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list7
Clinical Trials: see list2,530
Drug Prices:see low prices
DailyMed Link:sugammadex sodium at DailyMed

Pharmacology for Ingredient: sugammadex sodium

Ingredient-typegamma-Cyclodextrins
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-002Dec 15, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Organon Sub Merck
BRIDION
sugammadex sodium
SOLUTION;INTRAVENOUS022225-001Dec 15, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: sugammadex sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,670,340 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: sugammadex sodium

Country Document Number Estimated Expiration
China1241576► Subscribe
European Patent Office1210090► Subscribe
China1402737► Subscribe
South Africa200203538► Subscribe
MexicoPA02004940► Subscribe
MexicoPA02001545► Subscribe
Norway2010019► Subscribe
China1370073► Subscribe
World Intellectual Property Organization (WIPO)0140316► Subscribe
Peru09022001► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SUGAMMADEX SODIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
47/2008Austria► SubscribePRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTR√ĄGLICHES SALZ HIERVON
0Finland► Subscribe
2009 00002Denmark► Subscribe
1259550/01Switzerland► SubscribeFUSION; FORMER OWNER: ORGANON BIO SCIENCES NEDERLAND B.V., NL
C/GB08/057United Kingdom► SubscribePRODUCT NAME: SUGAMMADEX; REGISTERED: UK EU/1/08/466/001 20080725; UK EU/1/08/466/002 20080725
0356Netherlands► Subscribe
C031/2008Ireland► SubscribeSPC031/2008: 20090428, EXPIRES: 20230724
501Luxembourg► Subscribe91501, EXPIRES: 20230725
2008000068Germany► SubscribePRODUCT NAME: SUGAMMADEX ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
/2008Austria► SubscribePRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Julphar
Chinese Patent Office
Chubb
Cipla
Baxter
Queensland Health
Medtronic
Covington
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot